The stock of Aurinia Pharmaceuticals (NASDAQ: AUPH) was surging today after the company's second-quarter earnings call. A positive outlook for Lupkynis, its recently launched drug for lupus nephritis (LN), encouraged investors to drive the stock 21.5% higher as of 1:08 p.m. EDT on Friday.
All eyes were on Lupkynis sales when Aurinia reported second-quarter results after U.S. markets closed on Thursday. The company didn't disappoint, with product revenue that reached $6.6 million.
Image source: Getty Images.
For further details see:
Why Aurinia Pharmaceuticals Stock Was Surging on Friday